Different Forms of Genetic Testing: PGT-A and PGT-M

The advanced methodologies implemented in genetic screening include the detection of particular genetic defects, such as mutations or structural variations, with an analysis of chromosome numbers. Also, two key tests include PGT-A (Preimplantation Genetic Testing for Aneuploidy and PGT-M (Preimplantation Genetic Testing for Monogenic diseases). With PGT-A, the focus is on the number of chromosomes.

Embryos may have abnormal numbers of chromosomes, a condition known as aneuploidy. Also, PGT-A checks to confirm that the embryonic cells have the right number of chromosomes. It is significant because when there are too many or too few, then it will result in a miscarriage or birth defects. However, a bonus function of PGT-A is its ability to reveal the gender of each embryo that is being tested.

Oppositely, PGT-M pinpoints particular genetic diseases that are caused by alterations or mutations inherited from one or both parents. Also, this kind of genetic testing is the go-to choice for couples aware that they are carriers of monogenic diseases and want to prevent passing them on to their children.

A Look into PGT-A (Preimplantation Genetic Testing for Aneuploidy)

PGT-A or Preimplantation Genetic Testing for Aneuploidy is a medical method that is designed to examine embryos for an inconsistency in the number of chromosomes. However, sperm and egg cells will combine to form 46 chromosomes or 23 pairs, which is needed for healthy human development.

However, a deviation from the exact count, which might manifest as extra or missing chromosomes, is referred to as aneuploidy. Also, this abnormality majorly results in pregnancy loss, implantation failure, or a baby born with chromosomal abnormalities, the most common of which is Down Syndrome.

With such abnormalities that cannot be visibly recognized by observing embryos in an IVF laboratory, PGT-A serves as an effective solution. By identifying euploid embryos and those with the right number of chromosomes, this procedure enhances the success of embryo transfer considerably, reducing the risk of miscarriage.

A Deep Dive into PGT-M (Preimplantation Genetic Testing for Monogenic Diseases)

PGT-M, which is previously known as Preimplantation Genetic Diagnosis (PGD), centres around screening for particular genetic disorders. Also, these are monogenic disorders, conditions that can be caused by pathogenic changes in a single specific gene. However, monogenetic disorders can cause diseases like cystic fibrosis, Tay-Sachs disease, and Huntington's disease, among others.

PGT-M is suggested in some cases where one or both partners have a well-known family history of genetic conditions. For the couples who are carriers of such diseases, PGT-M can be a powerful tool to prevent transmitting genetic disorders to their offspring.

The main objective of PGT-M is to detect embryos unaffected by the inherited condition, ready for transfer. However, the method often necessitates the construction of a customized test for the couple. By integrating PGT-M into the reproductive plan, couples substantially lower the likelihood of having a child with a particular genetic disorder.

The Process of Genetic Testing in IVF

Embryo biopsy is a critical step in preimplantation genetic testing, as it involves extracting cells from an embryo for examination. However, the preparation for the biopsy begins by making an opening in the Zona Pellucida, which is a protective shell encasing the embryo. However, an embryologist can develop this opening using a laser, acid, or glass needle.

The embryonic cells required for the testing are either gently squeezed out or removed using suction through a pipette. Relying on the stage at which an embryo is biopsied, the process includes different considerations.

Day 3 Embryo Biopsy

Also known as blastomere, an embryo at this stage has only six to nine cells, while it is possible to perform genetic screening on just one cell, taking two offers more accurate results. One of the unique benefits of Day 3 biopsy is its capacity for fresh embryo transfer.

Well-known as a blastomere, an embryo at this stage contains only six to nine cells. While it is possible to perform genetic screening on just one cell, taking two offers more accurate results. One of the unique benefits of Day 3 biopsy is its capacity for fresh embryo transfer.

The embryonic cells needed for testing are either gently squeezed out or removed using the suction through a pipette, relying on the stage, which can enhance the risk of embryo arrest, which will result in less wait time and possibly lower expenses. Moreover, biopsy of more than one cell at this stage will enhance the risk of an embryo arrest, which will lead to halted development. Moreover, the risk of false positives and the inconclusive results is greater with a Day 3 biopsy.

Day 5 Embryo Biopsy

At this stage, known as the blastocyst stage, the embryo consists of hundreds of cells. A significant advantage of a Day 5 biopsy is the provision to take more cells for testing, leading to better diagnoses and fewer inconclusive results.

However, a setback is that not all embryos can endure lab conditions for this same duration. Also, Day 5 biopsy mandates the cryopreservation of embryos until the test results are available.

Despite these challenges, the ability to bypass an inherited genetic disease or increase the chances of successful IVF makes a strong case for embryo biopsy and associated genetic testing.